Genmab
- Market cap
- 22.54B
- P/E (TTM)i
- 28.97
- P/Bi
- 3.78
- EPSi
- 1.54
- Div yieldi
- 0.00%
- 52W posi
- 79%
Anonymous reader poll. Unscientific, not investment advice.
Genmab last traded at 36.65, down 3.04% on the session. At current prices, the business is worth about 22.54B, the #860 most valuable US-listed company we track. The trailing P/E of 28.20 is broadly in line with its five-year average of 30.15. Across 9 analysts the consensus rating is Buy, with an average price target of 40.00 (+9%). Against a 52-week band of 23.62-40.17, the shares are currently 79% of the way up.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 1 month.
- Recent price momentum is +18.9% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 0.8% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 30.4x | Better than 27% |
| Forward P/E | 25.5x | Better than 28% |
| Price / Sales | 5.4x | Better than 25% |
| P/E vs own 5-yr range | 49th pctl | Better than 60% |
Growth A-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 21.2% | Better than 85% |
| Net income CAGR (3Y) | 7.1% | Better than 53% |
| Free cash flow CAGR (3Y) | 29.8% | Better than 76% |
Profitability A
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 93.6% | Better than 98% |
| Operating margin | 33.6% | Better than 89% |
| Net margin | 25.9% | Better than 84% |
| Return on equity | 17.6% | Better than 62% |
| Return on invested capital | 10.9% | Better than 60% |
Momentum A-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 31.9% | Better than 93% |
| 6-month return | 39.2% | Better than 85% |
| 12-month return (ex latest month) | 0.9% | Better than 33% |
| Distance below 52-week high | 4.2% | Better than 92% |
Financial Health B+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 2.0x | Better than 68% |
| Debt to assets | 42.2% | Better than 35% |
| Interest coverage | 20.7x | Better than 80% |
| Free cash flow / net income | 117.4% | Better than 54% |
Analyst View C+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 88.9% | Better than 71% |
| Upside to average target | 4.0% | Better than 8% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 37.80
- Open
- 37.28
- Day range
- 36.27 - 37.87
- Avg price
- 36.99
- Volume
- 4.25M
- Turnover
- 157.35M
- Turnover ratei
- 0.74%
- Volume ratioi
- 0.59
- Amplitudei
- 4.23%
- 52-week rangei
- 23.62 - 40.17
Valuation
- P/Ei
- 23.85
- P/E (TTM)i
- 28.97
- P/Bi
- 3.78
- EPSi
- 1.54
- Book value / shi
- 9.69
- Net profit
- 945.11M
- Net assets
- 5.96B
Share structure
- Market cap
- 22.54B
- Float capi
- 21.10B
- Shares out
- 614.90M
- Float sharesi
- 575.61M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2019-07-18
8.8% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+63.26M net over the window
Short interest
- Shares short
- 4.92M
- % of floati
- 0.80%
- Days to coveri
- 3.17
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Genmab (GMAB)?
Genmab last traded at 36.65. The quote on this page refreshes every few seconds while US markets are open.
What is Genmab's market cap?
About 22.54B.
What is the P/E ratio of Genmab?
The trailing twelve-month P/E is 28.97, below its own 5-year average of 30.15 — in the middle of its historical range (48.68% percentile). See the Valuation tab for the full history.
Does Genmab pay a dividend?
Genmab does not currently pay a regular dividend.
Is Genmab a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 40.00, which implies 9.1% upside from the current price. This is not investment advice.
What is Genmab's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Genmab a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-08 08:18:19 · For reference only, not investment advice and not tailored to your situation.